April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
April 2024 in “Lasers in medical science” Lasers and light therapies are effective in promoting hair regrowth for different types of hair loss.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
April 2024 in “Journal of cosmetic dermatology” Children with alopecia areata have more exclamation mark hairs and fewer yellow dots than adults.
April 2024 in “Bioscience trends” Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
April 2024 in “Cosmetics” Wigs help improve self-esteem and quality of life for people with hair loss from alopecia areata.
April 2024 in “Skin research and technology” Minoxidil with triamcinolone acetonide is more effective for mild alopecia areata when injected with microneedles than when applied topically.
April 2024 in “Clinical dermatology review (Print)” Most women aged 20-40 in the study lost hair diffusely and in volume over 6 weeks to 6 months, mainly due to telogen effluvium, often without a clear cause.
April 2024 in “Dermatology and therapy” There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
March 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
March 2024 in “Homœopathic Links” Phosphorus homeopathy treatment led to complete hair regrowth in two Alopecia Areata patients.
March 2024 in “Clinical and experimental dermatology” Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
March 2024 in “Frontiers in Endocrinology” The study found that alopecia areata and hypothyroidism increase the risk of each other, but androgenetic alopecia and hypothyroidism do not.
March 2024 in “Nutrients” Alopecia Areata is linked to specific gut bacteria and metabolites, indicating a complex gut microbiome.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
March 2024 in “Skin research and technology” High CRP levels could indicate vitamin D deficiency in people with alopecia areata.
February 2024 in “Curēus” A balanced diet with proteins, vitamins, and minerals is crucial for managing skin disorders.
February 2024 in “Skin research and technology” LC-OCT is a promising tool for diagnosing and monitoring Alopecia areata.
February 2024 in “Biomedicines” Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.
February 2024 in “Lasers in Medical Science” Lasers and energy-assisted methods show promise for treating hair loss, but more research is needed.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
February 2024 in “Medicina-lithuania” Obesity and bariatric surgery can cause hair thinning and temporary hair loss due to nutritional deficiencies and stress.
February 2024 in “The Open dermatology journal” Alopecia Areata affects people of all ages worldwide, is likely caused by genetic and environmental factors, and can lead to stress and depression, highlighting the need for treatments that address both physical and mental health.
February 2024 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Most alopecia areata patients in the study were women, aged 15-49, with patchy hair loss and often had other health conditions.
January 2024 in “Dermatology practical & conceptual” Male gender and family history predict alopecia areata recurrence.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.